Brandon D Kirby

US Patent:

8395093, Mar 12, 2013

Filed:

Apr 6, 2010

Appl. No.:

12/754708

Inventors:

Frank Auffinger, III - Hamilton OH, US
Michael Richard Maddux - Jamestown OH, US
Kristopher Karl Aber - Cincinnati OH, US
Brandon Charles Kirby - Morgantown WV, US

Assignee:

Cornerstone Research Group, Inc. - Dayton OH

International Classification:

H05B 3/16
H05B 3/34

US Classification:

219543, 219546, 219549

Abstract:

The preferred embodiment utilizes metal coated high strain fabric reinforcement including but not limited to fiberglass, cotton fiber, or other materials that can undergo deformation, and various resin or elastomer compounds to create a conductive polymer whose resistivity and resistance remain essentially constant under a strain of approximately 0-150% or more. Additionally, the preferred embodiment utilizes a method of imprinting, depositing, etching, or embossing a design or pattern of conductive metal on fabric used in composites. The use of designs of conductive metals wrapped around a deformable core and the unique features of elastomeric polymers allows for their use as a flexible circuit board, formable heaters, and other various uses.

US Patent:

20210010096, Jan 14, 2021

Filed:

Mar 14, 2019

Appl. No.:

16/980198

Inventors:

- Huntington WV, US
Meagan W. Valentine - Huntington WV, US
Richard M. Niles - Huntington WV, US
Thomas Ryan Withers - Huntington WV, US
Brandon D. Kirby - Huntington WV, US

International Classification:

C12R 1/38
C08L 5/04
C12N 1/20

Abstract:

Bacterial cultures are provided that comprise a modified bacterium missing or deficient in two or more virulence factors. The two or more virulence factors can be selected from exotoxin A, hemolytic phospholipase C, phenazine-specific methyltransferase, alpha-1,3-rhamnosyltransferase, and 3-phosphoshikimate 1-carboxyvinyltransferase. Certain of the modified bacteria are also missing or deficient in one or more alginate acetylation enzymes including the alginate Oacetyltransferases AlgI, AlgJ, AlgF, AlgX, and/or the C5-mannuronan epimerase AlgG. Methods of producing alginate are also provided along with compositions comprising alginate produced by the modified bacteria.

US Patent:

20190365722, Dec 5, 2019

Filed:

Jun 3, 2019

Appl. No.:

16/429153

Inventors:

- Huntington WV, US
Thomas Ryan Withers - Huntington WV, US
Brandon Kirby - Bluefield WV, US

International Classification:

A61K 31/437
A61K 9/00
A61K 31/7036

Abstract:

Methods of treating a bacterial lung infection are provided and comprise administering an effective amount of rifaximin to a subject in need thereof. The rifaximin can be delivered by inhalation therapy, such as by delivering the rifaximin in aerosol form. The rifaximin is administered alone or in combination with tobramycin, including in multiple doses. Methods of reducing biofilm formation are also provided and comprise contacting a bacteria with an effective amount of rifaximin. Pharmaceutical composition are also included and comprise rifaximin and a pharmaceutically-acceptable vehicle suitable for administering the rifaximin in aerosol form.